Page 4,809«..1020..4,8084,8094,8104,811..4,8204,830..»

Aesthetic medicine – Wikipedia, the free encyclopedia

Posted: Published on October 31st, 2013

Aesthetic medicine is branch of medicine, distinct from plastic surgery, focused on satisfying the aesthetic desires and goals of patients. Aesthetic medicine comprises all medical procedures in the field of Aesthetics excluding all surgical procedures which require an operating table and general anesthesia (such as breast implants, liposuction, surgery of obesity, facelifts, rhinoplasty, etc.).[1] This specialty is primarily focused on the pathophysiology of aging skin, and adheres to scientific based procedures. Physicians practicing Aesthetic Medicine are trained in both invasive and non-invasive treatment modalities, and typically utilize a combination to meet the needs of the patient.[2] It can intervene The fields of competence are mesotherapy, the general medicine, biology, the dermatology, the endocrinology, gynecology, psychology.[3] Most current non-surgical aesthetic procedures: The real benefit of practicing Aesthetic Medicine is the type of care that physicians are offering to their patients. These procedures are elective and are performed on patients who do not suffer from illness. They are usually happy and in excellent health. They simply want a quick fix or a preventative procedure to help manage the normal effects of aging. When performed by a trained physician, non-surgical procedures are safer than plastic surgery as they do not require general anesthesia. … Continue reading →

Posted in Aesthetic Medicine | Comments Off on Aesthetic medicine – Wikipedia, the free encyclopedia

Dr. Darm Aesthetic Medicine – Plastic Surgery in Portland, Oregon

Posted: Published on October 31st, 2013

At Aesthetic Medicine in Portland, Oregon, Dr. Jerry Darm and his dedicated staff have promoted wellness, health, and beauty for over a decade. Over 50,000 procedures performed utilizing 25 different lasers and aesthetic devices have made Aesthetic Medicine one of the largest medical spas in the United States. BBB Accredited Business. Skin Problems Skin problems such as acne, rosacea, sun damage, pigmentation, scarring, unwanted hair, and moles can be safely and effectively treated with lasers and aesthetic devices. Wrinkles Fine lines, deep wrinkles, pore size,darkcirclesand overallskin textureare best treated with the LaserLift. This exclusive procedure combines microdermabrasion with three FDA approved lasers which rejuvenate and tighten the skin while building new collagen. Injectables Botox and Dysport are used to treat wrinkles in motion around the eyes and in the forehead. Injectable fillers including Juvederm and Restylane are used to fill in the deeper frown lines around the mouth and chin. Unwanted Fat / Cellulite Unwanted fat can be removed from the neck, arms, chest, abdomen, back, flanks and thighs using the unique LipoLift procedures developed at Aesthetic Medicine with minimum pain and downtime. We are one of the busiest centers in the United States and have performed over 3,000 LipoLift … Continue reading →

Posted in Aesthetic Medicine | Comments Off on Dr. Darm Aesthetic Medicine – Plastic Surgery in Portland, Oregon

D'AGE Sheep Placenta Extract / Stem Cell Therapy – Video

Posted: Published on October 31st, 2013

D'AGE Sheep Placenta Extract / Stem Cell Therapy D'AGE is one of our most precious project, we created the environment and incorporated sand glass into the visual, all the sand effects details was crafted with a lot of TLC. By: ExpressoFX … Continue reading →

Comments Off on D'AGE Sheep Placenta Extract / Stem Cell Therapy – Video

MS-UK | Stem cells And MS Research

Posted: Published on October 31st, 2013

Could skin tissue hold promise for treating Multiple Sclerosis?(30/10/13) Researchers in Milan, Italy reported that stem cells derived from mouse skin tissue were able to reduce nervous system damage in mice with a disease similar to multiple sclerosis, offering further evidence for the possibility that stem cells from patients might in the future be used for cell therapy to treat MS. The study, by Cecilia Laterza, Ph.D., Gianvito Martino, MD and colleagues at the San Raffaele Scientific Institute, Milan, and the University of Milan, was published today in Nature Communications. The study was co-funded by the National Multiple Sclerosis Society, Multiple Sclerosis Italian Foundation (FISM), MIUR Lombardy Region (NetLips Project), ELA Foundation, BMW Italy and NEUROKINE network (EU Framework 7 ITNproject). Current therapies for MS reduce the immune system attacks that damage the brain and spinal cord, but they are not effective in progressive phases of the disease, when damage to the protective myelin coating on nerve fibers and the nerve fibers themselves may be widespread. Finding ways to repair the nervous system to restore function is a major research priority. For this study the team used mouse skin stem cells and forced them through "cell reprogramming" to become myelin-making … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on MS-UK | Stem cells And MS Research

FDA approves Phase II of stem cell trial for ALS led by U-M's Dr …

Posted: Published on October 31st, 2013

ANN ARBOR, Mich. For nearly two years, University of Michigan neurologist Eva Feldman, M.D., Ph.D. has led the nations first clinical trial of stem cell injections in patients with the deadly degenerative disease known as amyotrophic lateral sclerosis, often called ALS or Lou Gehrigs disease. Now, a new approval from the U.S. Food and Drug Administration paves the way for U-M to become the second site in the trial, pending approval of the U-M Institutional Review Board. To date, the first phase of the trial has taken place at Emory University, with Feldman serving as principal investigator. The FDA approval of a Phase II trial was announced today by Neuralstem, the company whose product the trial is testing. The Phase II trial will continue to evaluate the safety of the stem cell injections, delivered directly into patients spinal cords in escalating doses of up to 400,000 cells per injection, with a maximum of 40 injections. It will also assess any signs that the injections might be impacting patients ALS symptoms or progression. Dr. Feldman discusses the FDA approval Feldman serves as an unpaid consultant to the company, and has led the analysis of results from the Phase I trial. In … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on FDA approves Phase II of stem cell trial for ALS led by U-M's Dr …

Stem Cell Therapeutics Receives U.S. Orphan Drug Designation for the Use of Tigecycline to Treat Acute Myeloid Leukemia

Posted: Published on October 31st, 2013

TORONTO, ONTARIO--(Marketwired - Oct 31, 2013) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS)(SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today announced that it has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) for the use of tigecycline in the treatment of acute myeloid leukemia (AML). Orphan Drug designation is granted to therapeutics treating rare diseases affecting less than 200,000 people in the U.S. The designation entitles the sponsor to seven years of market exclusivity as well as opportunities for additional funding and expert protocol assistance. "Orphan Drug status significantly enhances the commercial potential of tigecycline in AML, a disease which is notoriously difficult to treat," said the company's Vice President, Drug Development, Dr. Penka Petrova. "Through its unique mechanism of action and synergy with existing AML therapies, tigecycline has the potential to positively impact the standard of care in this disease." The company's program is based on Dr. Aaron Schimmer's published findings that tigecycline, an FDA-approved antibiotic, selectively targets leukemia cells and leukemic stem cells by inhibiting mitochondrial protein synthesis and thus shutting down the cells' energy supply. A Phase I Canadian and U.S. multicenter dose-escalation clinical trial in patients with relapsed or … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on Stem Cell Therapeutics Receives U.S. Orphan Drug Designation for the Use of Tigecycline to Treat Acute Myeloid Leukemia

New knowledge about serious muscle disease

Posted: Published on October 31st, 2013

PUBLIC RELEASE DATE: 31-Oct-2013 Contact: Malene Bech Vester-Christensen mbxc@novonordisk.com 45-22-15-25-89 University of Copenhagen About 3,000 people in Denmark suffer from one of the serious muscle-related diseases that come under the heading of muscular dystrophy. Some patients diagnosed with muscular dystrophy die shortly after birth, others become severely retarded and develop eye problems, while certain groups are confined to life in a wheelchair. Common to all muscular dystrophy sufferers is the difficulty of their muscle cells to attach themselves to each other and to the surrounding tissue. However, little is actually known about the root causes of the disease. New basic research from University of Copenhagen now offers insight into previously unknown facts about muscular dystrophy that may improve future diagnosis and treatment of the disease. The findings have just been published in the scientific journal PNAS (Proceedings of the National Academy of Science). "Our new research findings may shed light on some of the cellular processes that take place in connection with, for example, muscular dystrophy. This is important information because it is crucial for us to gain as detailed an understanding as possible about the individual cell components. Although the journey from the current basic research to any potential … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on New knowledge about serious muscle disease

The Northeast Regional Epilepsy Group (NEREG) offers What You Need to Know if Epilepsy Has Touched Your Child’s Life …

Posted: Published on October 31st, 2013

Hackensack, NJ (PRWEB) October 31, 2013 The program is meant for parents and health professionals alike. Continuing education credits for New Jersey nurses will be provided. Invited speaker and childhood epilepsy expert, Dr. John Pellock will discuss epilepsy emergencies in children, new medications for epilepsy and future therapies. He is joined by an exceptional group of epilepsy specialists who will lecture on new advances in diagnosis and treatment of epilepsy, epilepsy surgery, autism and epilepsy, infantile spasms, Tuberous Sclerosis, Lennox Gastaut Syndrome, Dravets Syndrome, and genetics in epilepsy. The Epilepsy Foundation of New Jersey will share know-how and local resources for parents and health providers. The conference is free of charge and is taking place on November 8 at the Hackensack University Medical Center at 30 Prospect Ave. Hackensack, NJ 07601--Hekemian Auditorium and Hekemian Conference Room 1 and will run from 9AM to 4PM. Breakfast and lunch are provided. To register, email events(at)epilepsygroup(dot)com, go to http://epilepsygroup.com/news_patients_providers6-20-2-142/what-you-need-to-know-if-epilepsy-has-touched-your-life.htm or call 201-643-6676. Dr. Marcelo Lancman, Director of Northeast Regional Epilepsy Group and board certified epileptologist, commented: This year we launched our second very ambitious educational program called What You Need to Know if Epilepsy Has Touched Your Life aimed to raise epilepsy and … Continue reading →

Comments Off on The Northeast Regional Epilepsy Group (NEREG) offers What You Need to Know if Epilepsy Has Touched Your Child’s Life …

FDA approves marijuana based drug

Posted: Published on October 31st, 2013

Published on: Thursday, October 31, 2013 By Bonnie Katz The U.S. Food and Drug Administration has approved clinical trials of a cannabis-based drug and its effects on epilepsy. The treatment, Epidiolex, is 98 percent purified cannabidiol (CBD) made by GW Pharmaceuticals based out of the U.K. There are around 60 known chemicals contained in cannabis called cannabinoids. Tetrahydrocannabinol, also known as THC, is the main component responsible for the drugs psychoactive nature. CBD, however, is the second most abundant cannabinoid in the cannabis and provides medicinal benefits without the high. Epidiolex will come in a viscous liquid form to be dispensed from syringes. A 25 milligram per meter or 100 milligram per meter will be the two strengths made available to those in the trials. The FDA has approved of intermediate-sized clinical trials sponsored by two doctors. Dr. Orrin Devinsky, a professor in the Department of Neurology, Neuroscience and Psychiatry in the New York University School of Medicine and director of the NYU Comprehensive Epilepsy Center, and Dr. Roberta Cilio, a pediatric neurologist at the University of California, San Francisco, are set to follow 25 patients using Epidiolex as treatment for pediatric epilepsy. On Oct. 4, at the NYU Langone … Continue reading →

Comments Off on FDA approves marijuana based drug

Working With Autism News Release: “Specialized Respite Services”

Posted: Published on October 31st, 2013

Los Angeles, Ventura, Santa Clarita, CA (PRWEB) October 31, 2013 Autism services organization, Working With Autism Inc. announced the start of a new Specialized Respite Services program. The service was designed to offer professional temporary relief to family members or other caregivers of children with autism. Working With Autisms launch of the program is aimed at further fostering well-being in the hundreds of families they serve. While in the WWA program, the client is provided with in-home, non-medical care, promoting their basic self-help needs and participation in other activities, while family members or caregivers are given a personal break from their role to attend to errands and appointments, engage in social activities or just take time for themselves. Dr. Hilya Delband, Director of Clinical Development and Marketing, explained what sets this service apart from the usual caregiving experience: Our respite care staff have training in applied behavior analysis (ABA) techniques and are therefore better equipped to manage any behavioral challenges that may arise when caring for a child with autism. In addition to having specialized behavioral education, WWA respite service staff hold current CPR and First Aid certifications and maintain regular crisis prevention intervention training to insure the safety of … Continue reading →

Comments Off on Working With Autism News Release: “Specialized Respite Services”

Page 4,809«..1020..4,8084,8094,8104,811..4,8204,830..»